Corsantrum Technology

Nintedanib Capsules Nindanib 100

PRODUCT INTRODUCTION

Nindanib 100 Soft Gelatin Capsule is used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer.

Nindanib 100 Soft Gelatin Capsule should be taken with food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Diarrhea is a very common side effect of this medicine. You are advised to drink plenty of fluids and inform your doctor if it does not go away. Other common side effects include nausea, abdominal pain, vomiting, abnormal liver function tests, loss of appetite, headache, weight loss, and high blood pressure. Your doctor might ask you for some blood tests to monitor liver functioning.

Before taking it, tell your doctor if have a bleeding problem, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding.

USES OF NINDANIB SOFT GELATIN CAPSULE

Idiopathic pulmonary fibrosis

Non-small cell lung cancer

BENEFITS OF NINDANIB SOFT GELATIN CAPSULE

In Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a lung disease caused by lung tissue becoming thick and stiff and eventually forming scar tissue within the lungs. The scarring, or fibrosis, seems to result from a cycle of damage and healing that occurs in the lungs. These changes are irreversible and the affected person may experience shortness of breath or dry cough as initial symptoms. Nindanib 100 Soft Gelatin Capsule kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells.

In Non-small cell lung cancer

Non-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Nindanib 100 Soft Gelatin Capsule helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor.

SIDE EFFECTS OF NINDANIB SOFT GELATIN CAPSULE

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Nindanib

Diarrhea

Nausea

Abdominal pain

Vomiting

Abnormal liver function tests

Loss of appetite

Headache

Weight loss

High blood pressure

HOW TO USE NINDANIB SOFT GELATIN CAPSULE

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Nindanib 100 Soft Gelatin Capsule is to be taken with food.

HOW NINDANIB SOFT GELATIN CAPSULE WORKS

Nindanib 100 Soft Gelatin Capsule is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

WHAT IF YOU FORGET TO TAKE NINDANIB SOFT GELATIN CAPSULE?

If you miss a dose of Nindanib 100 Soft Gelatin Capsule, skip it and continue with your normal schedule. Do not double the dose.

Nintedanib Capsules Nintib 150

PRODUCT INTRODUCTION

Nintib 150 Capsule is used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer.

Nintib 150 Capsule should be taken with food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Diarrhea is a very common side effect of this medicine. You are advised to drink plenty of fluids and inform your doctor if it does not go away. Other common side effects include nausea, abdominal pain, vomiting, abnormal liver function tests, loss of appetite, headache, weight loss, and high blood pressure. Your doctor might ask you for some blood tests to monitor liver functioning.

Before taking it, tell your doctor if have a bleeding problem, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

USES OF NINTIB CAPSULE

Idiopathic pulmonary fibrosis

Non-small cell lung cancer

BENEFITS OF NINTIB CAPSULE

In Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a lung disease caused by lung tissue becoming thick and stiff and eventually forming scar tissue within the lungs. The scarring, or fibrosis, seems to result from a cycle of damage and healing that occurs in the lungs. These changes are irreversible and the affected person may experience shortness of breath or dry cough as initial symptoms. Nintib 150 Capsule kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. You may experience some bothersome side effects. Discuss with your doctor if you have any doubts.

In Non-small cell lung cancer

Non-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Nintib 150 Capsule helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.

SIDE EFFECTS OF NINTIB CAPSULE

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Nintib

Diarrhea

Nausea

Abdominal pain

Vomiting

Abnormal liver function tests

Loss of appetite

Headache

Weight loss

High blood pressure

HOW TO USE NINTIB CAPSULE

Take this medicine in the dose and duration as advised by your doctor. Nintib 150 Capsule is to be taken with food.

WHAT IF YOU FORGET TO TAKE NINTIB CAPSULE?

If you miss a dose of Nintib 150 Capsule, skip it and continue with your normal schedule. Do not double the dose.

Nintedanib Capsules Nintena 150

PRODUCT INTRODUCTION

Nintena 150mg Soft Gelatin Capsule is used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer.

Nintena 150mg Soft Gelatin Capsule should be taken with food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Diarrhea is a very common side effect of this medicine. You are advised to drink plenty of fluids and inform your doctor if it does not go away. Other common side effects include nausea, abdominal pain, vomiting, abnormal liver function tests, loss of appetite, headache, weight loss, and high blood pressure. Your doctor might ask you for some blood tests to monitor liver functioning.

Before taking it, tell your doctor if have a bleeding problem, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

USES OF NINTENA SOFT GELATIN CAPSULE

Idiopathic pulmonary fibrosis

Non-small cell lung cancer

BENEFITS OF NINTENA SOFT GELATIN CAPSULE

In Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a lung disease caused by lung tissue becoming thick and stiff and eventually forming scar tissue within the lungs. The scarring, or fibrosis, seems to result from a cycle of damage and healing that occurs in the lungs. These changes are irreversible and the affected person may experience shortness of breath or dry cough as initial symptoms. Nintena 150mg Soft Gelatin Capsule kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. You may experience some bothersome side effects. Discuss with your doctor if you have any doubts.

In Non-small cell lung cancer

Non-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Nintena 150mg Soft Gelatin Capsule helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.

SIDE EFFECTS OF NINTENA SOFT GELATIN CAPSULE

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Nintena

Diarrhea

Nausea

Abdominal pain

Vomiting

Abnormal liver function tests

Loss of appetite

Headache

Weight loss

High blood pressure

HOW TO USE NINTENA SOFT GELATIN CAPSULE

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Nintena 150mg Soft Gelatin Capsule is to be taken with food.

WHAT IF YOU FORGET TO TAKE NINTENA SOFT GELATIN CAPSULE?

If you miss a dose of Nintena 150mg Soft Gelatin Capsule, skip it and continue with your normal schedule. Do not double the dose.

Nintedanib Capsules Nintena 100

PRODUCT INTRODUCTION

Nintena 100mg Soft Gelatin Capsule is used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer.

Nintena 100mg Soft Gelatin Capsule should be taken with food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Diarrhea is a very common side effect of this medicine. You are advised to drink plenty of fluids and inform your doctor if it does not go away. Other common side effects include nausea, abdominal pain, vomiting, abnormal liver function tests, loss of appetite, headache, weight loss, and high blood pressure. Your doctor might ask you for some blood tests to monitor liver functioning.

Before taking it, tell your doctor if have a bleeding problem, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding.

USES OF NINTENA SOFT GELATIN CAPSULE

Idiopathic pulmonary fibrosis

Non-small cell lung cancer

BENEFITS OF NINTENA SOFT GELATIN CAPSULE

In Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a lung disease caused by lung tissue becoming thick and stiff and eventually forming scar tissue within the lungs. The scarring, or fibrosis, seems to result from a cycle of damage and healing that occurs in the lungs. These changes are irreversible and the affected person may experience shortness of breath or dry cough as initial symptoms. Nintena 100mg Soft Gelatin Capsule kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. You may experience some bothersome side effects. Discuss with your doctor if you have any doubts.

In Non-small cell lung cancer

Non-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Nintena 100mg Soft Gelatin Capsule helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.

SIDE EFFECTS OF NINTENA SOFT GELATIN CAPSULE

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Nintena

Diarrhea

Nausea

Abdominal pain

Vomiting

Abnormal liver function tests

Loss of appetite

Headache

Weight loss

High blood pressure

HOW TO USE NINTENA SOFT GELATIN CAPSULE

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Nintena 100mg Soft Gelatin Capsule is to be taken with food.

WHAT IF YOU FORGET TO TAKE NINTENA SOFT GELATIN CAPSULE?

If you miss a dose of Nintena 100mg Soft Gelatin Capsule, skip it and continue with your normal schedule. Do not double the dose.

Nintedanib Capsules Nindanib 150

PRODUCT DETAILS

About Nindanib 150 Soft Gelatin Capsule 10's

Nindanib 150 Soft Gelatin Capsule 10's belongs to the category of 'anti-fibrotic medicine', and it is primarily used to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is an irreversible disease marked by a progressive decline in lung function. The tissues in the lungs become swollen and scarred over time, due to which it gets difficult to breathe deeply. The scarring makes it hard for the lungs to work properly.

Nindanib 150 Soft Gelatin Capsule 10's contains 'Nintedanib', which helps reduce the scarring and swelling in the lungs by decreasing the release/activity of naturally occurring growth factors in the body, allowing you to breathe better. Nindanib 150 Soft Gelatin Capsule 10's helps in slowing down the progress of idiopathic pulmonary fibrosis.

Always use this medicine as your doctor has told you or per the package leaflet. You must keep to your doctor's instructions to get the maximum benefit. In some cases, you may experience common side effects such as nausea, tiredness, diarrhoea, indigestion, loss of appetite, headache, and photosensitivity. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if you experience these side effects persistently.

Consult your doctor before taking Nindanib 150 Soft Gelatin Capsule 10's if you are pregnant or breastfeeding. Nindanib 150 Soft Gelatin Capsule 10's may cause tiredness and dizziness, so drive with caution. Avoid consuming alcohol with Nindanib 150 Soft Gelatin Capsule 10's as it could lead to increased dizziness. Nindanib 150 Soft Gelatin Capsule 10's is not recommended for children below 18 years as safety and effectiveness have not been established.

Uses of Nindanib 150 Soft Gelatin Capsule 10's

Idiopathic pulmonary fibrosis

Medicinal Benefits

Nindanib 150 Soft Gelatin Capsule 10's is an anti-fibrotic medicine used to treat idiopathic pulmonary fibrosis (IPF) in adults. Nindanib 150 Soft Gelatin Capsule 10's can help effectively slow the rate of lung function decline by 50%. Nindanib 150 Soft Gelatin Capsule 10's helps reduce the scarring and swelling in the lungs by decreasing the release/activity of naturally occurring growth factors in the body, allowing you to breathe better. Nindanib 150 Soft Gelatin Capsule 10's helps in slowing down the progress of idiopathic pulmonary fibrosis.

Directions for Use

Tablet/Capsule: Swallow it as a whole with water; do not crush, break or chew it.

Storage

Store in a cool and dry place away from sunlight

Side Effects of Nindanib 150 Soft Gelatin Capsule 10's

Diarrhoea

Feeling and being sick

Tummy (Abdominal) Pain

Loss of appetite and weight loss

Habit Forming

No

Diet & Lifestyle Advise

Watch out for triggers that worsen the cough, such as smoke, foods, air-conditioning, high altitude, etc.

Exercise moderately. Eat healthily.

Follow pulmonary rehabilitation program. It includes exercise, disease education, and group therapy.

Quit smoking and alcohol.

Get ample rest.

Include green leafy vegetables, sweet potatoes, broccoli, tomatoes, carrots, mangoes, citrus fruits, berries, and cocoa.

Lean proteins such as fish, meat, and poultry are the best.

Hydration is important. Drink plenty of water, herbal tea, and vegetable and fruit juices.

Avoid processed and refined foods.

Special Advise

Regular blood tests and occasional tests of your bone marrow will be carried out to check whether the treatment is working. If it does work, it will usually be taken for life.

Binimetinib is an oral drug used to treat lung cancer that is marketed under the LuciBinim 15 mg brand.  Mitogen-activated extracellular signal-regulated kinases 1 and 2 (MEK1/2), which are essential components of the MAPK/ERK signaling cascade, are selectively inhibited by it. When this route is altered, cancer cells may proliferate. The main use for binimetinib is the treatment of metastatic or incurable melanoma with BRAF V600E or V600K mutations; it is frequently used in conjunction with encorafenib.

Mechanism of Action

Binimetinib exerts its therapeutic effects by reversibly inhibiting MEK1 and MEK2 enzymes. These enzymes are upstream regulators of the ERK pathway, which, when aberrantly activated due to mutations like BRAF V600E/K, leads to uncontrolled cell division and tumor growth. By inhibiting MEK1/2, binimetinib disrupts this signaling cascade, thereby impeding tumor cell proliferation and survival.

Indications

LuciBinim 15 mg is indicated for:

• BRAF V600E or V600K mutations in unresectable or metastatic melanoma combined with encorafenib.
• BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC) treated with encorafenib.

Dosage and Administration

It is advised to take 45 mg of LuciBinim orally twice a day, about 12 hours apart, in addition to encorafenib. Skip the missed dose and proceed with the following dose as planned if a missed dose occurs within six hours of the next scheduled dose. 

Side Effects

Common side effects include:

• Fatigue
• Nausea
• Diarrhea
• Abdominal pain
• Vomiting

Serious adverse effects may encompass:

• Interstitial lung disease

Elevated liver enzymes (ALT, AST)

• Colitis
• Panniculitis
• Cardiomyopathy
• Visual disturbances, including serous retinopathy and retinal vein occlusion
• Venous thromboembolism and hemorrhage

Regular monitoring through blood tests and clinical assessments is recommended to detect and manage these potential side effects.

Storage

With acceptable deviations between 15°C and 30°C (59°F and 86°F), LuciBinim should be kept at room temperature, between 20°C and 25°C (68°F and 77°F). Keep the drug out of children's reach, in its original container, and properly closed. Keep it out of places like bathrooms that get a lot of heat and moisture.

Benefits

• Targeted Therapy: Specifically inhibits MEK1/2, providing a focused approach to treating BRAF-mutated cancers.
• Combination Efficacy: Works synergistically with encorafenib to improve outcomes in advanced melanoma.
• Oral Administration: Convenient dosing regimen that allows patients to take the medication at home.
• Proven Effectiveness: Demonstrated ability to extend progression-free survival in clinical trials for melanoma patients.
• Potential for Broader Applications: Under investigation for use in other cancers with MAPK pathway mutations.

Nintedanib Capsules cyendiv 150

PRODUCT DETAILS

About Cyendiv 150Mg 60 Capsule

Cyendiv 150Mg 60 Capsule belongs to the category of 'anti-fibrotic medicine', and it is primarily used to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is an irreversible disease marked by a progressive decline in lung function. The tissues in the lungs become swollen and scarred over time, due to which it gets difficult to breathe deeply. The scarring makes it hard for the lungs to work properly.

Cyendiv 150Mg 60 Capsule contains 'Nintedanib', which helps reduce the scarring and swelling in the lungs by decreasing the release/activity of naturally occurring growth factors in the body, allowing you to breathe better. Cyendiv 150Mg 60 Capsule helps in slowing down the progress of idiopathic pulmonary fibrosis.

Always use this medicine as your doctor has told you or per the package leaflet. You must keep to your doctor's instructions to get the maximum benefit. In some cases, you may experience common side effects such as nausea, tiredness, diarrhoea, indigestion, loss of appetite, headache, and photosensitivity. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if you experience these side effects persistently.

Consult your doctor before taking Cyendiv 150Mg 60 Capsule if you are pregnant or breastfeeding. Cyendiv 150Mg 60 Capsule may cause tiredness and dizziness, so drive with caution. Avoid consuming alcohol with Cyendiv 150Mg 60 Capsule as it could lead to increased dizziness. Cyendiv 150Mg 60 Capsule is not recommended for children below 18 years as safety and effectiveness have not been established. Cyendiv 150Mg 60 Capsule is listed as pregnancy category D. Because Cyendiv 150Mg 60 Capsule can cause harm to the fetus, women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Cyendiv 150Mg 60 Capsule.

Uses of Cyendiv 150Mg 60 Capsule

Idiopathic pulmonary fibrosis

Medicinal Benefits

Cyendiv 150Mg 60 Capsule is an anti-fibrotic medicine used to treat idiopathic pulmonary fibrosis (IPF) in adults. Cyendiv 150Mg 60 Capsule can help effectively slow the rate of lung function decline by 50%. Cyendiv 150Mg 60 Capsule helps reduce the scarring and swelling in the lungs by decreasing the release/activity of naturally occurring growth factors in the body, allowing you to breathe better. Cyendiv 150Mg 60 Capsule helps in slowing down the progress of idiopathic pulmonary fibrosis.

Directions for Use

Tablet/Capsule: Swallow it as a whole with water; do not crush, break or chew it.

Storage

Store in a cool and dry place away from sunlight

Side Effects of Cyendiv 150Mg 60 Capsule

Diarrhoea

Feeling and being sick

Tummy (Abdominal) Pain

Loss of appetite and weight loss

Habit Forming

No

Diet & Lifestyle Advise

Watch out for triggers that worsen the cough, such as smoke, foods, air-conditioning, high altitude, etc.

Exercise moderately. Eat healthily.

Follow pulmonary rehabilitation program. It includes exercise, disease education, and group therapy.

Quit smoking and alcohol.

Get ample rest.

Include green leafy vegetables, sweet potatoes, broccoli, tomatoes, carrots, mangoes, citrus fruits, berries, and cocoa.

Lean proteins such as fish, meat, and poultry are the best.

Hydration is important. Drink plenty of water, herbal tea, and vegetable and fruit juices.

Avoid processed and refined foods.

• Non-small cell lung cancer
• Pancreatic cancer

• Abdominal pain
• Bone pain
• Breathlessness
• Constipation
• Cough
• Diarrhea
• Fatigue
• Fever
• Infection
• Muscle pain
• Nausea
• Rash
• Stomatitis (Inflammation of the mouth)
• Vomiting
• Weight loss

LuciLazer 80mg is a branded formulation of Lazertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is specifically developed for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, particularly those with the T790M resistance mutation. LuciLazer offers a targeted, oral therapy approach for patients who have progressed on earlier-generation EGFR TKIs.

LuciLazer 80mg contains Lazertinib, an orally administered anti-cancer drug used in EGFR-mutated NSCLC. It is a potent and selective inhibitor of EGFR mutations, including the common activating mutations (exon 19 deletions and L858R) and the T790M resistance mutation, making it valuable in overcoming acquired resistance to first- and second-generation EGFR TKIs.

Lazertinib targets mutated EGFR in cancer cells. EGFR is a receptor tyrosine kinase that, when activated abnormally due to mutations, leads to uncontrolled cell division and tumor growth.

Lazertinib selectively:

• Binds irreversibly to the mutant EGFR kinase domain.

• Inhibits phosphorylation of EGFR and downstream signaling pathways such as PI3K/AKT and MAPK, essential for tumor cell proliferation and survival.

• Overcomes T790M mutation-based resistance seen in patients previously treated with other EGFR inhibitors like erlotinib or gefitinib.

• Its high selectivity for mutant EGFR reduces off-target toxicity, particularly sparing wild-type EGFR to minimize skin and gastrointestinal side effects.

LuciLazer 80mg is primarily indicated for:

• Advanced or metastatic NSCLC patients with EGFR T790M mutation.

• Patients whose disease has progressed on or after EGFR TKI therapy (like erlotinib or gefitinib).

• It may be used as a second-line or later-line treatment after confirmation of the mutation by an FDA-approved test.

• Standard Dosage: One tablet of LuciLazer 80mg taken orally once daily.

• It should be taken at the same time each day, with or without food.

• Swallow the tablet whole with water. Do not chew or crush.

LuciLazer 80mg, like all cancer therapies, may cause side effects. The most common and significant ones include:

• Rash

• Diarrhea

• Stomatitis (mouth sores)

• Decreased appetite

• Dry skin

• Nail inflammation (paronychia)

• Interstitial Lung Disease (ILD) or pneumonitis

• QT prolongation (affecting heart rhythm)

• Hepatotoxicity (elevated liver enzymes)

• Vision disturbances

• Bone marrow suppression

• Routine monitoring through blood tests, liver function tests, and ECGs is recommended during therapy.

LuciLazer 80mg offers several clinical advantages:

• Targeted Action: Specifically inhibits mutant EGFR without significantly affecting normal cells.

• Effective Against T790M Mutation: Works in patients resistant to first-line TKIs.

• Oral Convenience: Enables outpatient, daily at-home cancer treatment.

• Reduced Skin Toxicity: Less severe rash and diarrhea compared to older EGFR TKIs.

• CNS Penetration: Shows ability to cross the blood-brain barrier and help manage brain metastases in EGFR-mutated NSCLC.

Product introduction

Tecentriq 1200mg Injection belongs to a group of medicines called monoclonal antibodies. It is used in the treatment of non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, and melanoma.

Tecentriq 1200mg Injection is given as an injection into veins under the supervision of a doctor. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects.

The most common side effects of this medicine include fatigue, nausea, decreased appetite, constipation, cough, and shortness of breath. Some side effects such as chest pain, diarrhea, and dark urine might require immediate action. Inform your doctor if it bothers you, as there may be a way to prevent the side effects.

Uses of Tecentriq Solution for Infusion

• Treatment of Small cell lung cancer
• Non-small cell lung cancer
• Melanoma
• Treatment of Hepatocellular carcinoma

Benefits of Tecentriq Solution for Infusion

In Treatment of Small cell lung cancer

Small cell lung cancer (SCLC) is a disease in which malignant (cancer) cells form in the lung tissues. The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer has been found to result in significantly longer overall survival and progression-free survival than chemotherapy alone.

Side effects of Tecentriq Solution for Infusion

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Tecentriq

• Fatigue
• Weakness
• Decreased appetite
• Nausea
• Cough
• Breathlessness
• Constipation

How to use Tecentriq Solution for Infusion

Your doctor or nurse will give you this medicine. Kindly do not self-administer.

How Tecentriq Solution for Infusion works

Tecentriq 1200mg Injection is a type of monoclonal antibody. It works by blocking the activity of a protein located on the T cells- a type of white blood cells that regulate the functioning of the immune system. In the presence of Tecentriq 1200mg Injection, the killing power of T-cells is restored and the immune response is stimulated to locate and destroy cancer cells.

Safety advice

Alcohol

It is not known whether it is safe to consume alcohol with Tecentriq 1200mg Injection.

Breast feeding

Tecentriq 1200mg Injection is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.

Driving

It is not known whether Tecentriq 1200mg Injection alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.

Kidney

There is limited information available on the use of Tecentriq 1200mg Injection in patients with kidney disease.

Liver

There is limited information available on the use of Tecentriq 1200mg Injection in patients with liver disease.

Cobimetinib is a targeted medicine used to treat some types of cancer. It is sold under the Cotellic brand. It is especially advised for the treatment of adult patients with BRAF V600 mutations who have metastatic or incurable melanoma. It is administered in combination with vemurafenib, a BRAF inhibitor, to enhance therapeutic efficacy.

LuciCob 20 mg, containing the active ingredient cobimetinib, is a targeted therapy used in oncology. As a MEK inhibitor, it plays a crucial role in treating specific types of cancer. Below is a detailed guide covering its indications, dosage, side effects, storage, benefits, interactions, and more.

LuciCob 20 mg is primarily indicated for:

• Adult patients with melanoma that is unresectable or metastatic and with a BRAF V600E or V600K mutation should take vemurafenib in addition to it.

• Histiocytic Neoplasms: As a single agent for adult patients with histiocytic neoplasms.

• Before initiating treatment, confirm the presence of the BRAF V600 mutation through a validated test.

• Recommended Dose: 60 mg (3 tablets of 20 mg) once daily.

• Administration Schedule: Taken on a 28-day cycle:

• Days 1–21: 60 mg once daily.

• Days 22–28: No treatment (treatment break).

• Method of Administration: Oral intake, with or without food.

• Treatment Supervision: A trained medical professional with experience with anticancer medications should initiate and oversee treatment.

• Gastrointestinal: Diarrhea, nausea, vomiting.

• Dermatological: Rash, photosensitivity.

• Systemic: Fever (pyrexia).

• Cardiovascular: Cardiomyopathy.

• Hematologic: Lymphopenia.

• Ophthalmologic: Retinal vein occlusion.

• Hepatic: Hepatotoxicity

• Musculoskeletal: Elevated creatine phosphokinase (CPK), rhabdomyolysis.

• Regular monitoring is essential to manage these potential side effects.

LuciCob 20 mg offers several benefits in cancer treatment

• Targeted Therapy: Inhibits the MEK protein, crucial in the MAPK/ERK pathway, which is often overactive in certain cancers.

• Combination Therapy: When used with vemurafenib, it enhances the therapeutic effect in BRAF-mutated melanoma.

• Oral Administration: Provides a convenient oral dosage form, facilitating outpatient treatment.

These benefits contribute to improved outcomes in specific cancer types.

Erlotinib, the active ingredient of LuciErlo 150mg, a targeted anti-cancer drug, is mainly used to treat pancreatic and non-small cell lung cancer (NSCLC). It falls under the class of drugs known as tyrosine kinase inhibitors (TKIs) and specifically targets the epidermal growth factor receptor (EGFR). Manufactured as an oral tablet, LuciErlo offers a more tailored approach to cancer therapy by blocking the growth signals of cancer cells.

LuciErlo 150mg is a prescription drug designed to inhibit the activity of EGFR tyrosine kinase, a protein found in various cancer cells that promotes tumor growth and proliferation. The active component, erlotinib, works particularly well in people who have particular EGFR mutations, which are frequently observed in patients with lung cancer. It is marketed in India and other regions as a cost-effective alternative to brand-name Erlotinib formulations.

Erlotinib functions by selectively inhibiting the intracellular phosphorylation of tyrosine kinase associated with the EGFR. Many malignancies, especially non-small cell lung cancer, have mutations or overexpression of this receptor. By blocking EGFR activity:

• It inhibits signal transduction pathways that lead to cell proliferation.

• Promotes cell cycle arrest and apoptosis (programmed cell death).

• Limits tumor angiogenesis (formation of new blood vessels feeding the tumor).

LuciErlo 150mg is indicated for the treatment of:

• Non-Small Cell Lung Cancer (NSCLC) – Especially in patients with EGFR mutations and who have failed previous chemotherapy.

• Pancreatic Cancer: For individuals with locally advanced, incurable, or metastatic pancreatic cancer, in conjunction with gemcitabine.

• Off-label uses – In certain cases of head and neck cancers and other solid tumors with EGFR mutations (doctor discretion).

• Patients should be tested for EGFR mutations before starting therapy to ensure the best possible response.

Standard Dose:

• NSCLC: 150mg once daily.

• For Pancreatic Cancer (with gemcitabine): 100mg once daily.

Administration Instructions:

• Take LuciErlo at least one hour before or two hours after eating, as food increases drug absorption and can enhance side effects.

• Swallow the tablet whole with water, preferably at the same time each day.

• Skin Rash – Most frequent and often indicates effectiveness.

• Diarrhea

• Fatigue

• Anorexia and weight loss

• Nausea and vomiting

• Mouth sores

• Dry skin and itching

• Cough or shortness of breath

• Interstitial lung disease (ILD)

• Hepatotoxicity

• Gastrointestinal perforation

• Eye irritation or conjunctivitis

• Report any unusual or severe symptoms to a healthcare provider immediately.

• Targeted therapy: Particularly stops the growth of cancer cells in tumors that are EGFR positive.

• enhanced progression-free survival in individuals with EGFR mutations who had non-small cell lung cancer.

• Convenient oral formulation, no need for hospital-based IV administration.

• Well-tolerated compared to traditional chemotherapy.

• Delayed disease progression when used in advanced cancers.

A targeted cancer treatment called LuciLorla 25mg, which contains Lorlatinib, was created to address particular genetic abnormalities linked to non-small cell lung cancer (NSCLC). As an advanced third-generation ALK (anaplastic lymphoma kinase) and ROS1 tyrosine kinase inhibitor, it plays a pivotal role in managing patients whose cancers have evolved resistance to earlier treatments.

LuciLorla 25mg is a formulation of Lorlatinib, primarily prescribed to treat ALK-positive or ROS1-positive metastatic NSCLC. Lorlatinib is a potent, brain-penetrant kinase inhibitor designed to tackle resistant tumors that have progressed after treatment with first- or second-generation ALK inhibitors like Crizotinib, Ceritinib, or Alectinib.

Lorlatinib binds to and targets the tyrosine kinases ROS1 and ALK. These enzymes are responsible for the growth and survival of certain cancer cells. In patients with ALK-positive or ROS1-positive NSCLC, genetic alterations cause these kinases to be abnormally active. Lorlatinib selectively inhibits these enzymes, disrupting cell signaling pathways, halting tumor growth, and inducing apoptosis (programmed cell death).

A significant advantage of Lorlatinib is its ability to penetrate the blood-brain barrier, making it effective in treating brain metastases, which are common in ALK-positive NSCLC patients.

LuciLorla 25mg is used for:

• Metastatic non-small cell lung cancer (NSCLC) in patients who are ALK-positive and whose disease has progressed after treatment with other ALK inhibitors.

• Also indicated for patients with ROS1-positive NSCLC where other treatments may not be effective.

• Treatment should always be initiated under the supervision of an oncologist experienced in using anticancer medications.

Standard Dosage:

• The typical recommended dose is 25 mg orally once daily, with or without food.

• The tablet should be swallowed whole and should not be crushed, chewed, or split.

Lorlatinib, like other potent targeted therapies, can have side effects. Not every patient will experience all of them, but it's essential to monitor and manage them:

• Hypercholesterolemia and hypertriglyceridemia (elevated blood lipids)

• Edema (swelling of limbs)

• Peripheral neuropathy (numbness or tingling)

• Cognitive and mood effects (confusion, mood changes, speech difficulties)

• Fatigue

• Diarrhea or constipation

• Weight gain

• Joint pain

• Vision changes

• CNS effects: hallucinations, seizures, cognitive impairment

• Liver function abnormalities

• Pneumonitis

• QT prolongation (heart rhythm issue)

• Patients should have regular lipid profile checks, ECGs, liver function tests, and neurological assessments during treatment.

• Highly effective against resistant tumors: Especially in patients who have failed first- and second-line ALK inhibitors.

• CNS penetration: One of the few ALK inhibitors effective against brain metastases.

• Targeted therapy: Acts precisely on the mutated genes with minimal effect on normal cells, leading to better tolerance than traditional chemotherapy.

• Convenient oral administration: Enhances patient compliance.

A targeted cancer treatment called LuciLorla 25mg, which contains Lorlatinib, was created to address particular genetic abnormalities linked to non-small cell lung cancer (NSCLC). As an advanced third-generation ALK (anaplastic lymphoma kinase) and ROS1 tyrosine kinase inhibitor, it plays a pivotal role in managing patients whose cancers have evolved resistance to earlier treatments.

LuciLorla 25mg is a formulation of Lorlatinib, primarily prescribed to treat ALK-positive or ROS1-positive metastatic NSCLC. Lorlatinib is a potent, brain-penetrant kinase inhibitor designed to tackle resistant tumors that have progressed after treatment with first- or second-generation ALK inhibitors like Crizotinib, Ceritinib, or Alectinib.

Lorlatinib binds to and targets the tyrosine kinases ROS1 and ALK. These enzymes are responsible for the growth and survival of certain cancer cells. In patients with ALK-positive or ROS1-positive NSCLC, genetic alterations cause these kinases to be abnormally active. Lorlatinib selectively inhibits these enzymes, disrupting cell signaling pathways, halting tumor growth, and inducing apoptosis (programmed cell death).

A significant advantage of Lorlatinib is its ability to penetrate the blood-brain barrier, making it effective in treating brain metastases, which are common in ALK-positive NSCLC patients.

LuciLorla 25mg is used for:

• Metastatic non-small cell lung cancer (NSCLC) in patients who are ALK-positive and whose disease has progressed after treatment with other ALK inhibitors.

• Also indicated for patients with ROS1-positive NSCLC where other treatments may not be effective.

• Treatment should always be initiated under the supervision of an oncologist experienced in using anticancer medications.

Standard Dosage:

• The typical recommended dose is 25 mg orally once daily, with or without food.

• The tablet should be swallowed whole and should not be crushed, chewed, or split.

• Take it at the same time each day.

• If a dose is missed and less than 4 hours have passed since the usual time, it may be taken. Otherwise, skip the missed dose and continue with the next one.

• Avoid taking a double dose to make up for the missed one.

Lorlatinib, like other potent targeted therapies, can have side effects. Not every patient will experience all of them, but it's essential to monitor and manage them:

• Hypercholesterolemia and hypertriglyceridemia (elevated blood lipids)

• Edema (swelling of limbs)

• Peripheral neuropathy (numbness or tingling)

• Cognitive and mood effects (confusion, mood changes, speech difficulties)

• Fatigue

• Diarrhea or constipation

• Weight gain

• Joint pain

• Vision changes

• CNS effects: hallucinations, seizures, cognitive impairment

• Liver function abnormalities

• Pneumonitis

• QT prolongation (heart rhythm issue)

• Highly effective against resistant tumors: Especially in patients who have failed first- and second-line ALK inhibitors.

• CNS penetration: One of the few ALK inhibitors effective against brain metastases.

• Targeted therapy: Acts precisely on the mutated genes with minimal effect on normal cells, leading to better tolerance than traditional chemotherapy.

• Convenient oral administration: Enhances patient compliance.

LuciRepo 40mg contains Repotrectinib, an advanced targeted therapy designed to treat specific types of cancer with genetic alterations. As precision medicine evolves, Repotrectinib offers hope to patients whose tumors exhibit particular mutations. This drug is especially relevant in non-small cell lung cancer (NSCLC) with ROS1 rearrangements and NTRK gene fusions. LuciRepo, produced as oral capsules, marks a milestone in the treatment of genetically-driven tumors.

LuciRepo 40mg is a tyrosine kinase inhibitor (TKI) formulation of Repotrectinib. It is used to treat adult patients with solid tumors that have ROS1-positive NSCLC or NTRK gene fusion-positive cancers, including those who may have previously received other treatments. Repotrectinib is particularly potent against tumors with acquired resistance to prior TRK or ROS1 inhibitors.

Repotrectinib functions by selectively inhibiting tyrosine kinases, including:

• ROS1 (c-ros oncogene 1)

• TRKA, TRKB, and TRKC (tropomyosin receptor kinases encoded by NTRK1, NTRK2, NTRK3)

These kinases, when abnormally activated by gene fusions, drive cancer progression by promoting uncontrolled cell proliferation. Repotrectinib binds to these fusion kinases and blocks signaling pathways such as:

• PI3K/AKT

• RAS/MAPK

• JAK/STAT

By doing so, it halts tumor growth and may induce tumor regression. Its compact molecular structure allows it to penetrate the blood-brain barrier, making it useful in cases with brain metastases.

LuciRepo (Repotrectinib) is indicated for:

• Adult patients with non-small cell lung cancer (NSCLC) that is ROS1-positive.

• Solid tumors with NTRK gene fusion in adults and children aged 12 and up:

• Who have no satisfactory alternative therapy.

• Who have progressed after prior therapy.

• These indications are often determined after molecular testing confirms the genetic mutations (ROS1 or NTRK fusions).

Recommended Dosage for Adults:

• Initiation Phase (14 days): 160 mg orally once daily

• Maintenance Phase (after Day 14): 160 mg twice daily (BID)

• Capsules should be swallowed whole, with or without food. Do not crush, chew, or open the capsules.

• Dizziness

• Fatigue

• Constipation

• Dysgeusia (altered taste)

• Nausea

• Headache

• Anemia

• Weight gain

• CNS effects: Risk of dizziness and loss of balance due to CNS penetration

• QT prolongation: May affect heart rhythm—requires ECG monitoring

• Hepatotoxicity: Elevated liver enzymes (ALT, AST)

• Pneumonitis: Non-infectious lung inflammation

• Neurotoxicity: Cognitive and motor disturbances

• Immediate medical attention is needed for severe dizziness, chest pain, breathing difficulty, or confusion.

• Effective in resistant cancers: Works even after resistance to other TKIs like crizotinib or entrectinib.

• Brain metastases coverage: Crosses blood-brain barrier to treat intracranial tumors.

• Oral administration: Convenient daily capsule dosing.

• Precision medicine: Tailored to genetic mutations, offering targeted and often more effective treatment.

Ritlecitinib, a new experimental medication that falls under the class of selective ROS1/NTRK inhibitors, is a component of the targeted cancer treatment LuciRit 50mg. Designed for precision oncology, LuciRit targets genetic mutations found in specific tumors, making it an innovative choice in personalized cancer treatment. It is developed to treat patients with certain types of advanced or metastatic cancers, especially non-small cell lung cancer (NSCLC) that exhibits ROS1 gene rearrangements.

LuciRit 50mg (Ritlectinib) is an oral targeted therapy drug developed to inhibit ROS1 and NTRK gene fusions in cancer cells. These gene fusions result in uncontrolled cell proliferation and tumor growth. Ritlectinib blocks these abnormal signaling pathways, thereby inhibiting tumor growth and spread. It is a selective, potent, and brain-penetrant tyrosine kinase inhibitor (TKI), effective in both systemic and intracranial disease.

• Ritlectinib acts as a tyrosine kinase inhibitor (TKI) specifically designed to target: ROS1 (c-ros oncogene 1)

• Tropomyosin receptor kinases, or TRK family of receptors (NRK1, NTRK2, and NTRK3)

Gene-fused tumors have aberrant activation of these receptors. Ritlectinib selectively binds to the ATP-binding pocket of the kinase domain of these fusion proteins and inhibits phosphorylation, which stops downstream signaling pathways like MAPK/ERK and PI3K/AKT—key drivers of cancer cell survival, proliferation, and metastasis. This leads to apoptosis (programmed cell death) and reduction in tumor burden.

LuciRit 50mg is primarily indicated for:

• ROS1-positive metastatic non-small cell lung cancer (NSCLC)

• NTRK fusion-positive solid tumors (under clinical trials)

It may also be considered for cancers resistant to other ROS1 inhibitors like crizotinib, where Ritlectinib shows effectiveness against resistance mutations. This drug is typically prescribed after confirmation of gene fusions through next-generation sequencing (NGS) or FISH testing.

Recommended Dosage:

• The standard adult dose is Ritlectinib 50mg orally once or twice daily, based on physician discretion, body weight, and response.

Administration Instructions:

• Take with or without food.

• Swallow the tablet whole with water.

• Avoid crushing, chewing, or splitting.

• Take the medicine at the same time every day.

LuciRit 100mg (for titration or dose adjustment) Investigational pediatric doses under clinical trials

Dose Adjustments May Be Required:

• In cases of liver or kidney impairment

• When combined with strong CYP3A4 inhibitors or inducers

• If adverse reactions or drug toxicity occur

• Fatigue

• Constipation

• Nausea and vomiting

• Dizziness

• Diarrhea

• Increased liver enzymes (ALT, AST)

• Vision disturbances

• Hepatotoxicity (liver damage)

• QT prolongation (irregular heartbeat)

• CNS effects (headache, seizures)

• Myalgia or muscle weakness

• Pneumonitis (rare)

• Regular monitoring of liver function, ECG, and neurological status is recommended during treatment.

LuciSel 40mg contains Selpercatinib, a targeted cancer therapy developed to treat certain types of cancers driven by RET (Rearranged during Transfection) gene alterations. Patients with RET-altered non-small cell lung cancer (NSCLC), thyroid malignancies, and medullary thyroid carcinoma (MTC) can use this selective RET kinase inhibitor. LuciSel represents a significant advancement in precision oncology, offering improved outcomes with a better safety profile.

The oral anti-cancer drug LuciSel 40mg contains the selective RET inhibitor Selpercatinib. Tumor growth in several cancers is known to be fueled by RET gene mutations and fusions. Selpercatinib is specifically designed to inhibit these RET alterations, thus controlling the growth and spread of RET-driven tumors.

It is indicated for patients who test positive for RET gene fusions or mutations and have limited or no alternative treatment options.

Selpercatinib works by selectively inhibiting the RET tyrosine kinase receptor, a protein involved in cell proliferation and survival. RET gene alterations can lead to abnormal signaling pathways that cause cells to grow uncontrollably. These include:

• Fusions of the RET gene in papillary thyroid tumors and NSCLC

• RET gene mutations in medullary thyroid cancers

• By binding to the RET receptor, Selpercatinib blocks this abnormal signal, thereby reducing tumor growth, metastasis, and enhancing apoptosis (programmed cell death).

• It is also designed to penetrate the central nervous system (CNS), helping control brain metastases often seen in advanced lung cancers.

LuciSel 40mg is indicated for:

• Adults with RET fusion-positive non-small cell lung cancer (NSCLC).

• Thyroid Cancer (including Papillary Thyroid Cancer): Adults and children (≥12 years) with RET fusion-positive thyroid cancer that is refractory to radioactive iodine treatment.

• Systemic treatment is required for adults and children 12 years of age and older with RET-mutant medullary thyroid carcinoma (MTC).

• Before starting treatment, genetic testing is required for all patients to confirm RET mutations.

Recommended Dosage for Adults and Adolescents (≥12 years):

Body weight determines the dosage of sepercatinib:

• ≥50 kg: 160 mg orally twice daily

• <50 kg: 120 mg orally twice daily

Since LuciSel is available in 40mg strength, doses are usually adjusted by combining multiple capsules.

Administration Tips:

• Take on an empty stomach, at least 2 hours after food and 1 hour before the next meal.

• Swallow capsules whole with water. Do not crush, chew, or open.

• If a dose is missed, take it as soon as possible unless the next dose is due within 6 hours.

Like all medications, LuciSel can cause side effects. These are categorized into common, less common, and serious adverse events.

• Diarrhea or constipation

• Fatigue

• Dry mouth

• Hypertension

• Edema (swelling in hands/feet)

• Nausea and vomiting

• Headache

• Abdominal pain

• Liver enzyme elevation (ALT/AST)

• QT interval prolongation (heart rhythm issue)

• Bleeding events

• Hypersensitivity reactions

• Pneumonitis (lung inflammation)

• Regular blood tests and ECGs are required during therapy to monitor safety.

LUCISOT Sotorasib Tablets 120 mg represent a significant advancement in precision oncology, designed specifically to target a common mutation found in certain types of cancer. Manufactured under strict pharmaceutical standards, this oral therapy offers new hope to patients suffering from non-small cell lung cancer (NSCLC) with the KRAS G12C mutation. As one of the first approved targeted therapies for this mutation, Sotorasib marks a breakthrough in cancer treatment, potentially transforming outcomes for eligible patients.

LUCISOT, which is primarily used to treat non-small cell lung cancer (NSCLC) that has spread or become locally advanced, contains sotorasib, a KRAS G12C inhibitor. Adult patients whose condition has worsened after at least one previous systemic therapy are the only ones eligible for this medicine. Sotorasib is an oral tablet that helps inhibit the growth of cancerous cells by directly targeting the KRAS G12C mutation.

Sotorasib is a targeted therapy that inhibits the KRAS G12C mutation, a driver of tumor growth in various cancers, particularly NSCLC.

• KRAS gene: Normally regulates cell division. Mutations in KRAS can cause uncontrolled cell proliferation.

• G12C mutation: A particular KRAS mutation in which cysteine is substituted for glycine at position 12. Tumor development and sustained KRAS protein activation result from this.

• Sotorasib's action: It binds irreversibly to the KRAS G12C protein, locking it in an inactive GDP-bound state. This prevents downstream signaling in the MAPK pathway, thereby halting cell proliferation and promoting cancer cell death.

This targeted action means Sotorasib works only in tumors with the KRAS G12C mutation, minimizing damage to normal cells.

LUCISOT Sotorasib is indicated for:

• Patients with KRAS G12C mutations are particularly at risk for non-small cell lung cancer (NSCLC).

• Used after progression on prior systemic treatments, including immunotherapy or chemotherapy.

• Before prescribing, healthcare providers will confirm the presence of the KRAS G12C mutation using an FDA-approved diagnostic test.

• Recommended dose: 960 mg once daily, which typically equals eight 120 mg tablets taken at the same time.

• Mode of administration: Orally, with or without food.

• Tablet intake: Swallow tablets whole. Do not chew, crush, or split.

• Missed dose: If a dose is missed by more than 6 hours, skip it and take the next dose as scheduled.

• Vomiting after dose: Do not take an additional dose. Resume the next dose at the regular time.

Like all medications, LUCISOT may cause side effects. Common and serious adverse reactions include:

• Diarrhea

• Nausea

• Fatigue

• Musculoskeletal pain

• Elevated liver enzymes (ALT, AST)

• Cough

• Decreased appetite

• Hepatotoxicity: Elevated liver enzymes and bilirubin, requiring dose adjustments or discontinuation.

• Interstitial Lung Disease (ILD) or pneumonitis: May present as new or worsening respiratory symptoms.

• QT prolongation: Though rare, it can cause irregular heart rhythms.

• Patients should undergo routine liver function monitoring and report any signs of respiratory distress or liver dysfunction.

LuciPral 100mg contains the active ingredient Pralsetinib, a targeted cancer therapy developed to treat specific types of cancers that harbor RET (Rearranged during Transfection) gene alterations. Manufactured to offer precision medicine benefits, LuciPral is primarily used in the treatment of RET fusion-positive non-small cell lung cancer (NSCLC) and RET-mutant medullary thyroid cancer (MTC). Oncology has advanced significantly with its approval, especially for patients who have few options for targeted therapy.

LuciPral is an oral tyrosine kinase inhibitor (TKI) specifically designed to inhibit RET kinase activity. Lung and thyroid tumors are among the many cancer forms for which RET mutations are recognized oncogenic drivers. Adult patients with RET-mutant or RET-fusion-positive thyroid tumors and RET-fusion-positive non-small cell lung cancer are prescribed 100 mg of LuciPral.

Pralsetinib works by selectively inhibiting RET receptor tyrosine kinases, which are involved in cell growth and division. RET gene fusions and mutations cause abnormal signaling that drives cancer cell proliferation and survival. By binding to the ATP-binding pocket of the RET kinase, Pralsetinib inhibits its activity, thereby halting cancer progression and inducing cancer cell death.

This selective mechanism minimizes off-target effects on other kinases, leading to a more tolerable safety profile compared to non-selective inhibitors.

The following conditions can be treated with 100 mg of LuciPral:

• adults with non-small cell lung cancer (NSCLC) that has spread and is RET fusion positive.

• Adults and adolescents aged ≥12 who have progressed or metastatic RET-mutant medullary thyroid cancer (MTC) require systemic therapy.

• When appropriate, RET fusion-positive thyroid carcinoma that is resistant to radioactive iodine (RAI).

• This therapy is generally prescribed based on genetic testing that confirms RET mutations or fusions.

The usual recommended dose of LuciPral is:

• 400 mg once daily, which equals four 100 mg capsules taken orally on an empty stomach.

• Important: Avoid food intake for at least 2 hours before and 1 hour after taking the dose.

• Capsules should be swallowed whole, not crushed or chewed. Patients are advised to take the dose at the same time each day for consistent drug levels in the body.

Like all cancer therapies, LuciPral 100mg may cause side effects. Some common and serious side effects include:

• Constipation

• Hypertension

• Fatigue

• Musculoskeletal pain

• Diarrhea

• Anemia

• Rash

• Interstitial Lung Disease (ILD) or pneumonitis

• Hypertensive crisis

• Hepatotoxicity

• Bleeding events

• QT interval prolongation

• Neutropenia or thrombocytopenia

• Patients should report any difficulty breathing, unexplained bruising, liver symptoms (jaundice, dark urine), or chest pain immediately.

• Targeted Therapy: Specifically inhibits RET kinase with fewer off-target effects.

• High Response Rate: Demonstrated clinical activity in both treatment-naïve and previously treated patients.

• Oral Administration: Convenient daily oral dosage improves compliance.

• Rapid Onset of Action: Shows tumor shrinkage in a short time in many patients.

• Personalized Medicine: Enhances outcomes in patients with confirmed RET alterations.

Lorlatinib Tablets Lorbriqua 100 mg

About LORLATINIB

LORLATINIB belongs to the group of medicines that inhibit an enzyme called anaplastic lymphoma kinase (ALK). It is used to treat adults with advanced stages of lung cancer called non-small cell lung cancer (NSCLC). Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the lung tissues. There are several types of non-small cell lung cancer. Smoking is the major risk factor for non-small cell lung cancer.

LORLATINIB contains the active substance Lorlatinib, a medicine used to treat adults with advanced stages of a form of lung cancer called non-small cell lung cancer (NSCLC). It works by inhibiting a type of enzyme called tyrosine kinase and triggers the death of cancer cells in patients with alterations in genes for ALK. LORLATINIB is only given to patients whose disease is due to an alteration in the gene for ALK tyrosine kinase.

Always use this medicine as your doctor has told you or per the package leaflet. You must keep to your doctor's instructions to get the maximum benefit. In some cases, you may experience common side effects such as diarrhoea, constipation, joint pain, weight gain, headache, rash, and muscle pain. Most of these side effects do not require medical attention and will resolve gradually over time. 

Uses of LORLATINIB

Treatment of advanced stages of lung cancer called non-small cell lung cancer (NSCLC)

Medicinal Benefits

LORLATINIB is only given to patients whose disease is due to an alteration in the gene for ALK tyrosine kinase. It works by inhibiting a type of enzyme called tyrosine kinase and triggers the death of cancer cells in patients with alterations in genes for ALK.

Directions for Use

Swallow it as a whole with water; do not crush, break or chew it.

Storage

Store in a cool and dry place away from sunlight

Side Effects of LORLATINIB

• Increase in cholesterol and triglycerides

• Limb or skin swelling

• Double vision

• Pain

• Numbness

• Unusual sensations such as burning or pins and needles, difficulty walking, or difficulty with usual activities of daily

• Increased level of enzymes called lipase and/or amylase

• Anaemia

• Diarrhoea

• Constipation

• Pain in your joints

• Weight gain

• Headache

• Rash

• Muscle pain

Habit Forming

No

Diet & Lifestyle Advise

• Watch out for triggers that worsen the cough, such as smoke, foods, air-conditioning, high altitude, etc.

• Exercise moderately. Eat healthily.

• Follow pulmonary rehabilitation program. It includes exercise, disease education, and group therapy.

• Quit smoking and alcohol.

• Get ample rest.

• Include green leafy vegetables, sweet potatoes, broccoli, tomatoes, carrots, mangoes, citrus fruits, berries, and cocoa.

• Lean proteins such as fish, meat, and poultry are the best.

• Hydration is important. Drink plenty of water, herbal tea, and vegetable and fruit juices.

• Avoid processed and refined foods.

Special Advise

You will have blood tests before you start treatment and during your treatment. These tests check the level of cholesterol, triglycerides and the enzymes amylase or lipase in your blood before you start treatment with LORLATINIB and regularly during treatment. You will have blood tests before you start treatment and during your treatment. These tests check the level of cholesterol, triglycerides and the enzymes amylase or lipase in your blood before you start treatment with LORLATINIB and regularly during treatment.

Introduction :

Breast cancer, pancreatic cancer, and non-small cell lung cancer are all treated with the anti-cancer drug Nabcure 100MG Injection.

It is given as an injection by a qualified medical professional. Your doctor will determine the appropriate dosage and frequency of administration for you. This is based on the condition you are being treated for and is subject to change. You should follow your doctor's instructions to the letter. It can have potentially dangerous negative effects if taken improperly or in excess. The benefits might not become apparent to you for a few weeks or months, but you shouldn't stop taking it until your doctor instructs you to.

This medication frequently causes nausea, vomiting, and weakness as adverse effects. Serious side effects like hand and lip swelling, hair loss, and weight gain are also possible. Your doctor might advise taking additional medicine in addition to this to lessen these negative effects. But if you experience unusual bleeding or bruises, a sore throat, oral ulcers, or a high temperature, call your doctor right once (fever). Your blood's red and white blood cell counts could drop as a result of this medication, making you more susceptible to infections. You must have routine blood tests to monitor the health of your liver and blood cells.

Before taking it, tell your doctor if you have heart disease, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your doctor know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.


Uses :

Breast cancer

Non-small cell lung cancer

Pancreatic cancer


Side Effects :

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them.

Common side effects of Nabcure :

• Nausea
• Vomiting
• Weakness
• Low blood platelets
• Rash
• Upper respiratory tract infection
• Urinary tract infection
• Bleeding
• Anemia (low number of red blood cells)
• Flushing (sense of warmth in the face, ears, neck and trunk)
• Hair loss
• Decreased blood pressure
• Peripheral neuropathy (tingling and numbness of feet and hand)
• Diarrhea
• Decreased white blood cell count (neutrophils)

Rahika (Capmatinib 200mg) Tablet

PRODUCT INTRODUCTION

Rahika 200mg Tablet is used in the treatment of non-small cell lung cancer. This drug stops or slows down the growth of cancer cells.

Rahika 200mg Tablet should be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or more than the recommended dose can cause severe side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless the doctor tells you to.

Edema, nausea, musculoskeletal pain, fatigue, vomiting, dyspnea, cough, and decreased appetite are some common side effects of this medicine. Some serious side effects that might occur and need doctor consultation include tiredness, itchy skin, yellowing of the skin, chest pain or discomfort, and changes in the heartbeat. Your doctor may perform some blood tests before and after the treatment to check for liver or blood sugar levels.

Before taking Rahika 200mg Tablet, tell your doctor if you have heart disease, liver or kidney problems, or are taking any medicines to treat infections. Many other medicines can affect or be affected by this medicine; therefore, let your healthcare team know about all your medications. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during the treatment is important to avoid pregnancy.

USES OF RAHIKA TABLET

• Treatment of Non-small cell lung cancer

BENEFITS OF RAHIKA TABLET

In Treatment of Non-small cell lung cancer

Non-small cell lung cancer is one of the major kinds of lung cancer, affecting both smokers and non-smokers. Rahika 200mg Tablet helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine, and you should discuss the risks and benefits with your doctor. Avoid drinking alcohol while taking this treatment, and drink plenty of water to stay hydrated.

SIDE EFFECTS OF RAHIKA TABLET

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Rahika

• Edema (swelling)

• Nausea

• Musculoskeletal stiffness

• Breathlessness

• Fatigue

• Vomiting

• Cough

• Decreased appetite

HOW TO USE RAHIKA TABLET

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Rahika 200mg Tablet may be taken with or without food, but it is better to take it at a fixed time.

HOW RAHIKA TABLET WORKS

Rahika 200mg Tablet works by blocking the action of an abnormal protein that promotes the multiplication of cancer cells. This helps slow or stop the spread of cancer cells.

WHAT IF YOU FORGET TO TAKE RAHIKA TABLET?

If you miss a dose of Rahika 200mg Tablet, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.

• Non-small cell lung cancer

• Abdominal pain
• Bone pain
• Breathlessness
• Constipation
• Cough
• Diarrhea
• Fatigue
• Fever
• Infection
• Muscle pain
• Nausea
• Rash
• Stomatitis (Inflammation of the mouth)
• Vomiting
• Weight loss

• Non-small cell lung cancer

• Abdominal pain
• Bone pain
• Breathlessness
• Constipation
• Cough
• Diarrhea
• Fatigue
• Fever
• Infection
• Muscle pain
• Nausea
• Rash
• Stomatitis (Inflammation of the mouth)
• Vomiting
• Weight loss

Lucicapma 200mg,(Capmatinib)

Non-small cell lung cancer (NSCLC) is the main condition treated with LuciCapma 200mg, an advanced targeted cancer therapy that contains the active ingredient capmatinib. It belongs to a class of drugs known as MET kinase inhibitors, which target specific genetic mutations responsible for uncontrolled cancer growth. Manufactured as an oral tablet, LuciCapma is part of personalized medicine approaches, offering treatment specifically for patients whose tumors have a MET exon 14 skipping mutation.

What is LuciCapma 200mg (Capmatinib)?

LuciCapma 200mg is a prescription anticancer medication designed to inhibit the MET (mesenchymal-epithelial transition) receptor tyrosine kinase, which is overactive in certain types of cancer. Capmatinib is the first FDA-approved therapy for adult patients with metastatic NSCLC harboring a MET exon 14 skipping mutation. This mutation leads to excessive MET signaling, contributing to tumor growth and spread. By inhibiting this pathway, Capmatinib helps control the disease more effectively.

How it Works / Mechanism of Action

Capmatinib works by selectively targeting and inhibiting MET kinase, a protein encoded by the MET gene. In normal cells, MET is involved in cell growth, survival, and repair. However, in NSCLC with MET exon 14 skipping mutations, the MET signaling becomes overactive, leading to uncontrolled cancer cell proliferation, invasion, and metastasis.

Capmatinib binds to the ATP-binding site of the MET receptor, blocking downstream signaling pathways like RAS/MAPK, PI3K/AKT, and STAT, which are crucial for cancer cell survival and division. By halting this process, Capmatinib effectively induces cancer cell death and slows tumor progression.

How to Use / Indications

LuciCapma is indicated for:

· Adults with metastatic non-small cell lung cancer (NSCLC) that is positive for MET exon 14 skipping mutations, detected through an FDA-approved test.

· Individuals whose cancer has spread or who are unable to withstand immunotherapy or conventional chemotherapy.

· It's essential to confirm the presence of the MET exon 14 mutation through biomarker testing before initiating therapy.

How to Take / Dosage
Recommended Dosage:
 

· Capmatinib 400 mg orally twice daily (i.e., two 200 mg tablets twice a day).

· Can be taken with or without food.

· Swallow tablets whole with a glass of water. Do not crush, chew, or split the tablets.

· Treatment Duration: Continue until disease progression or unacceptable toxicity. Dose adjustments may be necessary based on side effects or liver function. 

LuciAda 200mg, (Adagrasib)

LuciAda 200mg is a generic formulation of Adagrasib, a targeted therapy. Adagrasib is an oral, irreversible inhibitor of the KRAS G12C mutation, a specific genetic alteration found in certain cancers, particularly non-small cell lung cancer (NSCLC). LuciAda is indicated for the treatment of adult patients with KRAS G12C–mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy

What Is LuciAda 200mg (Adagrasib)?

Adagrasib, the active ingredient in LuciAda 200mg, is a targeted medication intended to treat specific types of cancer. It is primarily utilized for:

• Non-Small Cell Lung Cancer (NSCLC): Specifically for patients with a KRAS G12C mutation who have experienced disease progression after prior therapies.
• Colorectal Cancer: For cases harboring the KRAS G12C mutation.
• Other solid tumors as identified in clinical trials.

Adagrasib is not a traditional chemotherapy drug. Instead, it is part of a newer class of drugs known as targeted therapies, which work by interfering with specific molecular pathways that help cancer cells grow and survive.

How Does LuciAda Work?

LuciAda’s active ingredient, Adagrasib, targets the KRAS G12C mutation, which is a common genetic driver in several types of cancer. In normal cells, the KRAS gene helps control cell division. When it is mutated (as in KRAS G12C), it can lead to uncontrolled cancer cell growth.

How to Use LuciAda 200mg

LuciAda 200mg comes in oral tablet form and is taken by mouth.

Side Effects

Common side effects of LuciAda include:

• Gastrointestinal: Diarrhea, nausea, vomiting.
• Hematologic: Anemia, decreased appetite.
• General: Fatigue, musculoskeletal pain, edema.

Serious adverse effects may include:

• Liver toxicity: Elevated ALT, AST, or bilirubin
• Prolonged QT interval: Potential for irregular heartbeats
• Interstitial Lung Disease (ILD) or Pneumonitis: Inflammation of lung tissue
• Kidney function changes
• Electrolyte imbalances

LuciAfa 40mg, (Afatinib)

LuciAfa 40 mg (Afatinib) represents a powerful and targeted therapy option for patients with EGFR-mutant NSCLC. Its mechanism of irreversibly inhibiting multiple ErbB receptors translates to significant clinical benefits, particularly in progression-free survival. 

LuciAfa 40mg is the generic version of Afatinib, a tyrosine kinase inhibitor (TKI) that fights cancer. It is primarily used to treat non-small cell lung cancer (NSCLC), especially in patients who have certain mutations in the EGFR gene.

Mechanism of Action

LuciAfa 40 mg is a generic formulation of Afatinib, a second-generation tyrosine kinase inhibitor (TKI) used primarily in the treatment of non-small cell lung cancer (NSCLC) with specific mutations in the epidermal growth factor receptor (EGFR) gene. 

Afatinib is an irreversible tyrosine kinase inhibitor (TKI) of the second generation.  It works by targeting and permanently blocking multiple members of the ErbB family of receptors, including:

• EGFR (ErbB1)
• HER2 (ErbB2)
• ErbB3
• ErbB4

These receptors are part of signaling pathways that control cell division, survival, and growth. In some cancers—especially NSCLC—mutations in EGFR lead to continuous, uncontrolled activation of these pathways, causing cancer cells to multiply rapidly.

Dosage and Administration

LuciAfa should be taken exactly as prescribed by your healthcare provider.

• Recommended Dose: 40 mg orally once daily.
• Administration: Take at least one hour before or two hours after a meal, on an empty stomach.
• Missed Dose: Take the missed dose as soon as you remember it if it has been more than 12 hours since the last dose. Don't double up; omit the missing dose if there are fewer than 12 hours left.

Side Effects

Common adverse effects include:

• Gastrointestinal: Diarrhea, nausea, vomiting, loss of appetite.
• Dermatological: Acne, dry skin, rash, mouth sores.
• Ocular: Eye irritation, visual disturbances.
• Other: Fatigue, cough, abdominal pain.

Serious side effects may involve:

• Interstitial lung disease (ILD) is characterized by fever, coughing, and dyspnea.
• Hepatotoxicity: Elevated liver enzymes, jaundice.
• Cardiac: Symptomatic left ventricular dysfunction.

Regular patient monitoring is necessary to look for these possible negative effects.

Benefits

• Targeted therapy effectively controls tumors by specifically inhibiting EGFR mutations.
• Irreversible Binding: Provides sustained receptor inhibition, enhancing therapeutic efficacy.
• Oral Administration: Convenient daily oral dosing improves patient compliance.
  
  

The targeted medication LuciBriga 90mg, which contains the active ingredient Brigatinib, is authorized to treat metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive. It provides a substitute for individuals who have advanced on crizotinib or who are intolerant to it because it is a second-generation ALK inhibitor.

What is LuciBriga 90mg (Brigatinib)?

LuciBriga is a branded formulation of Brigatinib, a tyrosine kinase inhibitor that specifically targets ALK mutations in cancer cells. By inhibiting ALK, Brigatinib disrupts the signaling pathways that drive tumor growth and survival, thereby slowing disease progression in ALK-positive NSCLC patients.

Mechanism of Action

Brigatinib inhibits the activation of the ALK kinase domain by attaching itself to its ATP-binding site. This inhibition blocks downstream signaling pathways involved in cell proliferation and survival, leading to reduced tumor growth. Brigatinib is also effective against ALK mutations that confer resistance to crizotinib, including the G1202R mutation.

Indications

For the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer, LuciBriga 90mg is recommended:

• As a first-line therapy
• After progression on or intolerance to crizotinib
• Using it on young patients is not advised.

Dosage and Administration

The following dosage schedule is advised for brentinib:

• Days 1–7: 90 mg orally once daily
• Day 8 and beyond: Increase to 180 mg orally once daily
• Tablets can be taken with or without food, and they should be swallowed whole. During therapy, stay away from grapefruit and grapefruit juice.

Dosage Modifications

In the event of negative responses, dose modifications can be required:

• First reduction: From 180 mg to 120 mg daily
• Second reduction: From 120 mg to 90 mg daily
• Third reduction: From 90 mg to 60 mg daily
• Do not raise your intake of bragitinib after stopping it.

Side Effects

Common adverse reactions include:

• Nausea
• Diarrhea
• Fatigue
• Headache
• Cough

Serious adverse reactions may include:

• Interstitial lung disease/pneumonitis
• Hypertension
• Bradycardia
• Visual disturbances
• Elevated creatine phosphokinase (CPK) levels
• Elevated lipase/amylase levels
• Hepatotoxicity
• Hyperglycemia
• Photosensitivity
• Regular monitoring is recommended to detect and manage these adverse effects.

Storage

Store LuciBriga tablets in their original, labeled container at room temperature between 20°C to 25°C (68°F to 77°F). Keep them away from excess heat and moisture, and out of reach of children and pets. 

Benefits

When treating ALK-positive non-small cell lung cancer, bragitinib has shown effective, providing:

• Improved progression-free survival compared to crizotinib in clinical trials
• Activity against crizotinib-resistant ALK mutations
• A manageable safety profile with appropriate monitoring
• These benefits contribute to its role as a preferred treatment option in the management of ALK-positive NSCLC.

LuciCer 150mg is a targeted anticancer medication containing Ceritinib, a selective ALK (anaplastic lymphoma kinase) inhibitor. It is specifically made to treat non-small cell lung cancer (NSCLC) in people who have mutations in the ALK gene. This drug has provided new hope for patients who have developed resistance to first-generation ALK inhibitors or who are newly diagnosed with ALK-positive NSCLC.

LuciCer 150mg is a prescription oral medication used to treat ALK-positive metastatic NSCLC, particularly when other treatments have failed or are unsuitable. The active ingredient, ceritinib, is a second-generation ALK inhibitor that has been approved by international regulatory agencies such as the US FDA and EMA. It is currently offered in various places as branded generics like LuciCer.

Ceritinib targets abnormal ALK proteins produced due to gene rearrangements (most notably EML4-ALK fusion) found in certain lung cancer cells. These altered proteins drive cancer cell growth and survival. By attaching itself to ALK's ATP-binding site and preventing its kinase activity, its:

• Blocking downstream signaling pathways (e.g., PI3K/AKT, JAK/STAT, RAS/MEK),

• Stopping cancer cell proliferation,

• Inducing apoptosis (programmed cell death).

• This highly selective inhibition makes LuciCer more effective in ALK-positive tumors, especially in cases where resistance to crizotinib (a first-generation ALK inhibitor) has occurred.

LuciCer is indicated for the treatment of adult patients with ALK-positive metastatic NSCLC. This is confirmed using an FDA-approved diagnostic test that detects ALK gene rearrangements.

Off-label indications are under investigation and include other ALK-positive solid tumors, but such use should be strictly guided by an oncologist.

LuciCer can cause a variety of side effects, some common and some serious. Regular monitoring by a healthcare provider is necessary.

• Nausea and vomiting

• Diarrhea

• Abdominal pain

• Fatigue

• Decreased appetite

• Constipation

• Rash

• Elevated liver enzymes (ALT, AST)

• Hepatotoxicity (liver damage)

• Interstitial lung disease (ILD)/pneumonitis

• QT interval prolongation (heart rhythm disturbance)

• Hyperglycemia (high blood sugar)

• Bradycardia (slow heart rate)

• Pancreatitis

• If any severe symptoms appear (e.g., shortness of breath, chest pain, jaundice, severe fatigue), medical attention should be sought immediately.

LuciCer provides significant benefits to a specific group of NSCLC patients:

• Targeted action: Directly inhibits the molecular driver (ALK) of the tumor.

• Effective in crizotinib-resistant cases: Active even when resistance develops.

• Increased survival: Increases overall response rates (ORR) and progression-free survival (PFS).

• Oral dosing: Enables convenient at-home treatment.

• CNS activity: Helpful for individuals with brain metastases, it has been demonstrated to permeate the central nervous system.

LuciDac 15mg is the brand name for dacomitinib, a targeted drug used to treat non-small cell lung cancer (NSCLC). It is a tyrosine kinase inhibitor (TKI) that specifically targets and inhibits the epidermal growth factor receptor (EGFR) pathway, which is often dysregulated in various cancers. By blocking this pathway, dacomitinib helps to slow down or stop the growth of cancer cells.

Dacomitinib functions by permanently attaching itself to the EGFR, HER2, and HER4 receptors' ATP-binding site. This binding prevents the phosphorylation and activation of these receptors, thereby inhibiting downstream signaling pathways that promote cell proliferation and survival. This mechanism is particularly effective in cancers with activating mutations in the EGFR gene.

LuciDac 15mg is primarily indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test. It is also considered for patients who have progressed on or after platinum-based chemotherapy.

Recommended Dosage: The recommended dose of LuciDac is 45 mg orally once daily.

Administration: It should be taken at roughly the same time every day, with or without food.

Missed Dose: Unless the following dose is practically due, if a dose is missed, it should be taken as soon as remembered. If so, do not take two doses at once; instead, omit the missing one.

• Diarrhea: May be severe and lead to dehydration.

• Rash: Acneiform rash is common and may require management.

• Mucosal Inflammation: Includes stomatitis and mouth sores.

• Decreased Appetite and Weight Loss: May affect nutritional status.

• Interstitial Lung Disease (ILD): Symptoms include cough, dyspnea, and fever.

• Hepatotoxicity: Elevated liver enzymes may indicate liver injury.

• Cardiac Events: QT interval prolongation has been observed.

• Patients should be monitored regularly for these adverse effects.

Efficacy: In clinical trials, a notable progression-free survival was shown.

Convenience: Intravenous infusions are not necessary when oral delivery is used.

Targeted Action: Selective inhibition of EGFR mutations reduces impact on normal cells.

LuciDac 45mg is the brand name for dacomitinib, a targeted drug used to treat non-small cell lung cancer (NSCLC). It is a tyrosine kinase inhibitor (TKI) that specifically targets and inhibits the epidermal growth factor receptor (EGFR) pathway, which is often dysregulated in various cancers. By blocking this pathway, dacomitinib helps to slow down or stop the growth of cancer cells.

Dacomitinib functions by permanently attaching itself to the EGFR, HER2, and HER4 receptors' ATP-binding site. This binding prevents the phosphorylation and activation of these receptors, thereby inhibiting downstream signaling pathways that promote cell proliferation and survival. This mechanism is particularly effective in cancers with activating mutations in the EGFR gene.

LuciDac 45mg is primarily indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test. It is also considered for patients who have progressed on or after platinum-based chemotherapy.

Recommended Dosage: The recommended dose of LuciDac is 45 mg orally once daily.

Administration: It should be taken at roughly the same time every day, with or without food.

Missed Dose: Unless the following dose is practically due, if a dose is missed, it should be taken as soon as remembered. If so, do not take two doses at once; instead, omit the missing one.

• Diarrhea: May be severe and lead to dehydration.

• Rash: Acneiform rash is common and may require management.

• Mucosal Inflammation: Includes stomatitis and mouth sores.

• Decreased Appetite and Weight Loss: May affect nutritional status.

• Interstitial Lung Disease (ILD): Symptoms include cough, dyspnea, and fever.

• Hepatotoxicity: Elevated liver enzymes may indicate liver injury.

• Cardiac Events: QT interval prolongation has been observed.

• Patients should be monitored regularly for these adverse effects.

Efficacy: In clinical trials, a notable progression-free survival was shown.

Convenience: Intravenous infusions are not necessary when oral delivery is used.

Targeted Action: Selective inhibition of EGFR mutations reduces impact on normal cells.

LuciEntre 100mg is a targeted therapeutic medication that contains the potent oral tyrosine kinase inhibitor (TKI) entrectinib. Non-small cell lung cancer (NSCLC) and other solid tumor forms that test positive for particular genetic abnormalities are its main uses. By blocking abnormal proteins that fuel cancer cell growth, LuciEntre offers a personalized and effective approach to cancer treatment.

LuciEntre 100mg is a prescription anticancer drug developed for the treatment of cancers that harbor ROS1 or NTRK gene fusions. These are genetic changes that cause cancer cells to develop out of control. Entrectinib is intended to stop the spread of cancer by blocking the action of these gene fusions.

It is particularly effective in treating:

• ROS1-positive NSCLC

• NTRK fusion-positive solid tumors (regardless of the tumor's origin)

Several tyrosine kinases are targeted and inhibited by entrectinib:

• ROS1 (c-ros oncogene 1)

• NTRK1/2/3 (neurotrophic tyrosine receptor kinase)

• ALK (anaplastic lymphoma kinase)

• These kinases are essential for cell survival, proliferation, and signaling. When mutated or abnormally fused with other genes, they drive malignant growth. Entrectinib binds to the ATP-binding site of these kinases, blocking their function and leading to cancer cell death or reduced tumor growth.

• Notably, Entrectinib has the ability to cross the blood-brain barrier, offering effectiveness even in cancers with brain metastases.

LuciEntre 100mg is indicated for:

• Patients whose tumors show the ROS1 gene fusion are said to have ROS1-positive metastatic non-small cell lung cancer (NSCLC).

• NTRK fusion-positive solid tumors – including rare or treatment-resistant cancers in adult and pediatric patients over 12 years, where surgical resection is not feasible or standard treatments have failed.

• Molecular testing is essential before initiating therapy to confirm ROS1 or NTRK gene fusions.

Like all cancer therapies, LuciEntre 100mg can cause side effects, though not everyone experiences them.

• Fatigue

• Constipation

• Dizziness

• Altered sense of taste (dysgeusia)

• Nausea or vomiting

• Weight gain

• Edema (swelling)

• Cognitive effects (e.g., confusion)

• Congestive heart failure

• QT interval prolongation (heart rhythm problem)

• Central nervous system effects (hallucinations, memory issues)

• Liver enzyme elevation

• Fractures

• Vision disorders

• Monitoring: Patients should undergo regular liver function tests, cardiac monitoring (ECG), and neurological assessments throughout treatment.

• Targeted therapy minimizes harm to healthy cells by focusing on tumors that have ROS1 or NTRK fusions.

• Effective against brain metastases: Crosses the blood-brain barrier.

• Tumor-agnostic therapy: NTRK-positive solid tumors can be treated regardless of the tumor’s location.

• Oral administration: Convenient dosing, no hospital infusion required.

• Rapid response: Patients often show tumor shrinkage within weeks.

LuciEntre 200mg is a targeted therapeutic medication that contains the potent oral tyrosine kinase inhibitor (TKI) entrectinib. Non-small cell lung cancer (NSCLC) and other solid tumor forms that test positive for particular genetic abnormalities are its main uses. By blocking abnormal proteins that fuel cancer cell growth, LuciEntre offers a personalized and effective approach to cancer treatment.

LuciEntre 200mg is a prescription anticancer drug developed for the treatment of cancers that harbor ROS1 or NTRK gene fusions. These are genetic changes that cause cancer cells to develop out of control. Entrectinib is intended to stop the spread of cancer by blocking the action of these gene fusions.

It is particularly effective in treating:

• ROS1-positive NSCLC

• NTRK fusion-positive solid tumors (regardless of the tumor's origin)

Several tyrosine kinases are targeted and inhibited by entrectinib:

• ROS1 (c-ros oncogene 1)

• NTRK1/2/3 (neurotrophic tyrosine receptor kinase)

• ALK (anaplastic lymphoma kinase)

• These kinases are essential for cell survival, proliferation, and signaling. When mutated or abnormally fused with other genes, they drive malignant growth. Entrectinib binds to the ATP-binding site of these kinases, blocking their function and leading to cancer cell death or reduced tumor growth.

• Notably, Entrectinib has the ability to cross the blood-brain barrier, offering effectiveness even in cancers with brain metastases.

LuciEntre 200mg is indicated for:

• Patients whose tumors show the ROS1 gene fusion are said to have ROS1-positive metastatic non-small cell lung cancer (NSCLC).

• NTRK fusion-positive solid tumors – including rare or treatment-resistant cancers in adult and pediatric patients over 12 years, where surgical resection is not feasible or standard treatments have failed.

• Molecular testing is essential before initiating therapy to confirm ROS1 or NTRK gene fusions.

Like all cancer therapies, LuciEntre 200mg can cause side effects, though not everyone experiences them.

• Fatigue

• Constipation

• Dizziness

• Altered sense of taste (dysgeusia)

• Nausea or vomiting

• Weight gain

• Edema (swelling)

• Cognitive effects (e.g., confusion)

• Congestive heart failure

• QT interval prolongation (heart rhythm problem)

• Central nervous system effects (hallucinations, memory issues)

• Liver enzyme elevation

• Fractures

• Vision disorders

• Monitoring: Patients should undergo regular liver function tests, cardiac monitoring (ECG), and neurological assessments throughout treatment.

• Targeted therapy minimizes harm to healthy cells by focusing on tumors that have ROS1 or NTRK fusions.

• Effective against brain metastases: Crosses the blood-brain barrier.

• Tumor-agnostic therapy: NTRK-positive solid tumors can be treated regardless of the tumor’s location.

• Oral administration: Convenient dosing, no hospital infusion required.

• Rapid response: Patients often show tumor shrinkage within weeks.

Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor included in the targeted oncology drug LuciGefi 250mg. This oral therapy is designed primarily for patients diagnosed with non-small cell lung cancer (NSCLC), especially those who have specific EGFR mutations. By targeting abnormal growth signaling in cancer cells, LuciGefi offers a more personalized approach to cancer treatment with better outcomes for eligible patients.

LuciGefi 250mg is a prescription medication used in the management of certain types of lung cancer. The active ingredient, Gefitinib, is a first-generation EGFR tyrosine kinase inhibitor (TKI). It blocks specific pathways that cancer cells use to grow and divide uncontrollably. Gefitinib is typically used in patients whose tumors have mutations in the EGFR gene, which are often detected through a diagnostic test.

Gefitinib works by preventing the epidermal growth factor receptor's (EGFR) tyrosine kinase activity. In many cancers, especially non-small cell lung cancers, mutations in the EGFR gene result in constant activation of this receptor, leading to uncontrolled cell proliferation and tumor growth.

LuciGefi binds to the intracellular tyrosine kinase domain of EGFR, blocking the phosphorylation and activation of downstream signaling proteins involved in cell division and survival. This targeted mechanism makes LuciGefi particularly effective in tumors with EGFR-activating mutations, such as exon 19 deletions or exon 21 (L858R) substitutions.

Indications for LuciGefi 250mg include:

• First-line treatment of patients with EGFR-mutant metastatic NSCLC.

• Treatment of patients who have failed prior chemotherapy regimens and whose cancer has progressed due to EGFR mutation-positive status.

• It is not effective in patients with wild-type EGFR or other mutations not sensitive to Gefitinib.

Standard Dosage:

• 250 mg orally once daily, with or without food.

• LuciGefi should be taken at the same time every day. The tablets should not be chewed, broken, or crushed; instead, they should be eaten whole with water.

Note: Treatment should only be started after confirming EGFR mutation-positive status using an approved diagnostic test.

Like all cancer treatments, LuciGefi can cause side effects. Common and serious side effects include:

• Diarrhea

• Rash or acne-like skin eruptions

• Dry skin

• Nausea and vomiting

• Fatigue

• Loss of appetite

• Eye irritation or conjunctivitis

• Interstitial Lung Disease (ILD) – potentially fatal; presents with new or worsening respiratory symptoms.

• Hepatotoxicity: Regular monitoring of liver function is necessary.

• Gastrointestinal perforation

• Severe skin reactions – including Stevens-Johnson syndrome (rare).

• Ocular toxicity – such as corneal ulceration or keratitis.

• Patients should contact their healthcare provider immediately if they notice severe or unusual symptoms.

• Targeted therapy: Acts specifically on cancer cells with EGFR mutations.

• Convenient oral administration: No hospital visits required for infusion.

• Improved progression-free survival: Demonstrated in several clinical trials in EGFR-mutant NSCLC patients.

• Better quality of life: Less systemic toxicity compared to traditional chemotherapy.

LuciMob 40mg is a brand name for the drug Mobocertinib, an oral medication designed specifically to treat a rare subset of non-small cell lung cancer (NSCLC). It is a targeted therapy developed to inhibit mutated proteins that drive the growth of cancer cells, particularly in patients with EGFR exon 20 insertion mutations, which are generally resistant to conventional EGFR inhibitors. Precision oncology has advanced significantly with this drug.

Mobocertinib is a tyrosine kinase inhibitor (TKI) used in the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations. These mutations are relatively rare and found in approximately 2% of NSCLC cases, making LuciMob a vital therapeutic option for a niche patient group.

It is typically prescribed after progression on or after platinum-based chemotherapy, as part of second-line or subsequent treatments.

Mobocertinib selectively targets and binds to mutant EGFR proteins, particularly those with exon 20 insertion mutations. These mutations cause EGFR to remain active even in the absence of signaling molecules, promoting uncontrolled cancer cell division.

Mobocertinib inhibits the autophosphorylation of EGFR and blocks the signaling pathways (MAPK/ERK and PI3K/AKT pathways) essential for tumor growth and survival. Unlike first- and second-generation EGFR TKIs, it is designed to accommodate the structural changes caused by exon 20 insertions, making it more effective for these mutations.

LuciMob (Mobocertinib) is specifically indicated for:

• Adults with advanced or metastatic NSCLC

• who have EGFR exon 20 insertion mutations in their malignancies

• After failure of platinum-based chemotherapy

• It is not indicated for patients with wild-type EGFR or those who haven't undergone molecular testing confirming the mutation.

Recommended Dosage:

• 160 mg once daily (which is four tablets of LuciMob 40mg)

• To be taken on an empty stomach, at least 1 hour before or 2 hours after a meal

• It should be taken at the same time every day with a full glass of water.

• Diarrhea (most prevalent)

• Nausea and vomiting

• Rash

• Dry skin

• Fatigue

• Decreased appetite

• QT interval prolongation (can lead to cardiac arrhythmia)

• Interstitial lung disease (ILD)/pneumonitis

• Hepatotoxicity (elevated liver enzymes)

• Dehydration and electrolyte imbalance (from severe diarrhea)

• Patients should be regularly monitored with ECGs, liver function tests, and symptom assessment.

• Targeted Action: Specifically inhibits EGFR exon 20 insertion mutations, improving efficacy.

• Oral administration offers greater ease and patient compliance.

• Clinical Benefit: Shows significant improvement in progression-free survival and overall response rates in clinical trials.

• Treatment Option: Fills an unmet need for patients with rare EGFR mutations unresponsive to traditional EGFR inhibitors.

Tepotinib is an ingredient in the targeted oral anticancer medicine LuciTepo 225mg, which is a member of the MET inhibitor pharmacological class. It is specifically designed to treat non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations—a genetic alteration that can drive cancer growth. As a precision therapy, Tepotinib is part of a growing movement toward personalized oncology, helping patients receive treatments tailored to their specific cancer genetics.

LuciTepo 225mg is a pharmaceutical formulation of Tepotinib, developed to treat adult patients with metastatic NSCLC whose tumors have alterations in the MET gene, particularly MET exon 14 skipping mutations. These mutations lead to overactivation of the MET pathway, promoting tumor progression, metastasis, and resistance to therapy.

Approved under accelerated programs in several countries, Tepotinib is an option for patients who have limited responses to conventional therapies.

Tepotinib is a MET tyrosine kinase inhibitor (TKI) that is selective. The MET gene encodes a receptor tyrosine kinase that regulates several cellular functions such as growth, survival, and motility. In some NSCLC cases, exon 14 skipping leads to increased MET activity due to impaired protein degradation.

By binding to the MET receptor, Tepotinib inhibits its autophosphorylation and downstream signaling cascades, particularly the PI3K/AKT, RAS/ERK, and STAT3 pathways. This inhibition results in:

• Reduced tumor cell proliferation

• Decreased survival of MET-dysregulated cancer cells

• Suppression of metastasis

• Tepotinib is a very good treatment for cancers that skip MET exon 14 because of this mechanism.

Indications:

LuciTepo 225mg is indicated for:

• Patients with proven MET exon 14 skipping mutations may develop metastatic non-small cell lung cancer (NSCLC).

• Before initiating treatment, genomic testing is essential to confirm the presence of the MET mutation. This ensures that only eligible patients receive Tepotinib, improving treatment efficacy and avoiding unnecessary side effects.

Standard Dosage:

• It is advised to take two 225 mg pills with food for a dose of 450 mg once daily.

• Taking the dose with food enhances the bioavailability of the drug and ensures better absorption into the bloodstream.

• Missed Dose: If a dose is missed, it can be taken as soon as remembered on the same day. Skip if it's close to the next dose.

• Renal Impairment: Mild to moderate renal impairment does not require a change in dosage.

• Hepatic Impairment: In patients with moderate liver impairment, monitoring is recommended. Severe impairment requires caution.

The most commonly reported include:

• Peripheral edema (swelling of hands/feet)

• Nausea

• Diarrhea

• Fatigue

• Increased liver enzymes (ALT, AST)

• Hypoalbuminemia

• Decreased appetite

• Interstitial lung disease (ILD): Rare but potentially fatal. Promptly report new or worsening respiratory symptoms.

• Increased liver enzymes indicate hepatotoxicity; routine liver function testing is advised.

• Electrolyte imbalances: For example, low potassium or sodium levels.

• QT interval prolongation: Heart rhythm disturbances in rare cases.

• Patients should be monitored routinely, especially during the initial phase of treatment.

LuciAle 150mg, (Alectinib)

Alectinib, a strong and specific inhibitor of anaplastic lymphoma kinase (ALK), is available in generic form as LuciAle 150 mg. It is primarily used in the treatment of ALK-positive non-small cell lung cancer (NSCLC), particularly in patients who have progressed on or are intolerant to crizotinib, another ALK inhibitor.

What is LuciAle 150 mg (Alectinib)?

• LuciAle 150 mg is a targeted cancer therapy that contains the active ingredient Alectinib, a second-generation ALK (anaplastic lymphoma kinase) inhibitor.
• It is used to treat non-small cell lung cancer (NSCLC) in patients whose tumors are ALK-positive, meaning they have a specific genetic alteration (a rearrangement in the ALK gene) that drives the cancer’s growth.
• LuciAle helps slow or stop the growth of cancer cells and is particularly effective in controlling brain metastases, a common issue in ALK-positive lung cancer patients.

Mechanism of Action     

Targeting ALK Mutations:

• In some NSCLC patients, the ALK gene becomes abnormally rearranged (most commonly fusing with the EML4 gene).
• An aberrant ALK protein produced by this EML4-ALK fusion promotes unchecked cell proliferation, development, and dissemination, ultimately resulting in cancer.

Inhibiting the ALK Protein:

• Alectinib attaches itself to the ALK fusion protein's tyrosine kinase domain.
• It blocks the ALK signaling pathway, thereby inhibiting tumor cell proliferation and inducing apoptosis (cell death) in ALK-positive cancer cells.

Dosage and Administration

• Recommended Dose: 600 mg (four 150 mg capsules) taken twice daily with food.
• Administration: Drink a glass of water after swallowing the capsules full. It is not recommended to open, chew, or dissolve the capsules.
• Missing Dose: To make up for a missing dose, avoid taking two doses at once.

Side Effects

Common side effects include:

• Gastrointestinal: Nausea, vomiting, diarrhea, constipation, abdominal pain.
• Hematologic: Anemia, neutropenia.
• Musculoskeletal: Muscle pain, weakness.
• Dermatologic: Rash, photosensitivity.
• Neurological: Headache, dizziness.
• Respiratory: Cough, interstitial lung disease (ILD).

Serious adverse effects may involve:

• Hepatotoxicity: Monitor liver function tests regularly.
• Bradycardia: Symptomatic bradycardia may require dose adjustment or discontinuation.
• Hemolytic Anemia: Monitor for signs of anemia; may require dose modification.

Storage

• Temperature: Keep below 30°C (86°F) at room temperature.
• Access: Keep out of children's reach.

Benefits

• Efficacy: Demonstrated significant improvement in progression-free survival in ALK-positive NSCLC patients.
• CNS Penetration: Effective against brain metastases, a common site of progression in ALK-positive NSCLC.
• Convenience: Twice-daily oral dosing with food enhances patient compliance.

LuciAle 150 mg provides a powerful, targeted, and well-tolerated treatment option for patients living with ALK-positive lung cancer, especially those at risk of brain metastases.